Catalyst overview
Research summary
This catalyst tracks a Phase 3 data readout for NBTXR3 +/- Cetuximab in Head and neck cancer. The expected timing is based on the latest available company guidance and may change.
06/02/26:- NANORAY-312 Ph3 amendment reiterated; final analysis expected H1 2027, event-driven.
Verification
Confirm timing and program details against the company announcement or filing.